HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection

Hepatocarcinoma Clinical Trial

Official title:

Hepatic Artery Infusion Chemotherapy(HAIC) Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05311319
• Other study ID #: 2021-GZWK-03
• Status: Recruiting
• Phase: Phase 2
• Start date: January 11, 2022
• Est. completion date: December 2023

Study information

• Verified date: March 2022
• Source: Fudan University
• Contact: Lu Wang, PhD
• Phone: +86-18121299357
• Email: w.lr[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single center, non-randomized, open, multi-cohort clinical, exploratory Phase II study, to evaluate the efficacy and safety of HAIC combined with TQB2450 and anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after resection.

Description:

The high incidence of HCC recurrence following liver resection is a serious issue. However, no adjuvant therapy has been widely recognized at present. Interventional therapy and systemic drug therapy are common treatment methods and effective treatment for liver cancer. The combination of multiple drugs may reduce the recurrence in HCC patients with high-risk recurrence. TQB2450 is a humanized monoclonal antibody of programmed death-ligand1 (PD-L1), enabling T cells to restore immune activity and thus enhance the immune response. Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and proliferative signaling.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 2023
• Est. primary completion date: December 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Eastern Cooperative Oncology Group performance status (ECOG-PS): 0-1;

2. The expected survival is more than 3 months;

3. Histologically or cytologically diagnosed as HCC;

4. After hepatectomy, satisfy any of the following recurrence factors: a) microvascular invasion (MVI); b) Single tumor diameter = 8cm; c) The tumor grew infiltratively, unclear boundary and no complete capsule; d) Multiple tumor nodules =3, or nodules<3 but the diameter of a single tumor is > 3cm; e) With portal vein, hepatic vein or cholangiocarcinoma thrombus; f) tumor ruptured or invaded adjacent organs before surgery.

5. hepatitis B virus (HBV) DNA<2000IU/mL;

6. Liver function status Child-Pugh grade A (=6);

7. The main organs function well.

8. Laboratory inspection met the following criteria: Hemoglobin (Hb) =8.0 g/L, Neutrophils (ANC) = 1.5×10^9/L, Platelet count (PLT) = 60×10^9/L, Total bilirubin (TBIL) =3.0 mg/dL, albumin=28 g/L, Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase= 5.0 ×upper limit of normal, International Prothrombin Standardization Ratio (INR) = 2.3, Thyroid-stimulating hormone (TSH) =upper limit of normal;

9. The woman patients of childbearing age who must agree to take contraceptive methods during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it.

10. Voluntary participation and written informed consent;

Exclusion Criteria:

1. History of another malignancy tumor , except for the cured skin basal cell carcinoma and cervical carcinoma in situ)

2. Other adjuvant therapy after surgery, such as targeted drugs, programmed death-1 (PD-1) antibody and other immunotherapy, FOLFOX systemic chemotherapy;

3. The imaging examination showed residual tumor after the surgical resection;

4. Patients with previous liver transplantation or preparation for liver transplantation.

5. Patients who are allergic to components of TQB2450 and anlotinib or pharmaceutical excipients;

6. Received any live attenuated vaccine within 4 weeks of admission or during the study period;

7. Patients with a history of immunodeficiency (or autoimmune disease), or other acquired congenital immunodeficiency diseases.

8. Hypertension which cannot be well controlled by antihypertensive drugs (systolic blood pressure = 150 mmHg or diastolic blood pressure = 100 mmHg).

9. A history of gastrointestinal bleeding within 3 months before enrollment;

10. A history of arterial and venous thrombotic events within 6 months before enrollment, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis and pulmonary embolism;

11. Hereditary or acquired hemorrhagic and thrombotic tendencies, such as hemophilia, coagulation dysfunction, thrombocytopenia, hypersplenism, etc.

12. Pts need to long-term anticoagulant therapy;

13. Participated in any other drug clinical studies within 3 months before enrollment;

14. A history of psychotropic substance abuse or drug abuse;

15. Patients with concomitant diseases which could seriously endanger their own safety or could affect the completion of the study according to investigators' judgment;

Related Conditions & MeSH terms

• Carcinoma, Hepatocellular
• Hepatocarcinoma
• Recurrence

Intervention

Drug:
• HAIC+TQB2450+Anlotinib
HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Disease Free Survival (DFS)	DFS defined as the time from date of randomization until the date of recurrence or death due to any cause	24 months
Secondary	Overall survival (OS)	OS defined as the time from date of randomization until the date of death due to any cause	24 months
Secondary	Time to recurrence (TTR)	TTR defined as the time from date of randomization until the date of recurrence.	24 months
Secondary	Safety: adverse events	adverse events (AEs) categorized by severity in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0.	24 months